From: Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy
WNT
p-value
WT
MUT
N (%)
TAZneg
39 (76.5)
12 (23.5)
0.008 (Chi-squared)
TAZpos
17 (48.6)
18 (51.4)
YAPneg
7 (70.0)
3 (30.0)
0.999 (Fisher)
YAPpos
49 (64.5)
27 (35.5)